The fully human CTLA-4 inhibitor, tremelimumab, was first tested in advanced, HCV-associated HCC patients, showing a response rate (RR) of 17%, a median time to progression (TTP) of 6.5 months and a probability of 1 year survival of 43% (181). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.